Form PTO-1449 (modified)	Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's	Applicant: Sunil Chada *et al.*	
INFORMATION DISCLOSURE STATEMENT		
(Use several sheets if necessary)	Filing Date: December 7, 2001	Group: 1633

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	See Page 1	See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C272	Chada *et al.*, "mda-7/IL24 Kills Pancreatic Cancer Cells by Inhibition of the Wnt/PI3K Signaling Pathways: Identification of IL-20 Receptor-Mediated Bystander Activity against Pancreatic Cancer," *Mol. Ther.*, 11(5):724-733, 2005.
	C273	Inoue *et al.*, "Inhibition of Src Kinase Activity by Ad-mda7 Suppresses Vascular Endothelial Growth Factor Expression in Prostate Carcinoma Cells," *Mol. Ther.*, 12:707-715, 2005.
	C274	Mellinghoff *et al.*, "Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors," *New Eng. J. Med.*, 353:2012-2024, 2006.
	C275	Normano *et al.*, "The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib," *J. Cell Physiol.*, 207:420-427, 2006.
	C276	Sutter *et al.*, "Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer," *Int. J. Cancer*, 118:1814-1822, 2006.
	C277	Xia *et al.*, "A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer," *Proc. Natl. Acad. Sci. USA*, 103:7795-7800, 2006.

25784843.1

EXAMINER: /Q. Janice Li/ (03/06/2008)	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /qjl/